MedPath

Effectiveness and Safety of Rhubarb for the Treatment of Patients Who Have Suffered From Cerebral Hemorrhage

Phase 2
Conditions
Lung Infection
Cerebral Hemorrhage
Pneumonia
Interventions
Drug: Placebo
Registration Number
NCT00815737
Lead Sponsor
Fudan University
Brief Summary

This study will determine if rhubarb will reduced the incidence of pneumonia and improved recovery from an acute cerebral hemorrhage. The study is designed to look at both infection rate and overall recovery and recovery of motor function, for example muscle strength and coordination.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Occurrence of an acute cerebral hemorrhage (between 9 and 72 h after onset) with a score of at least 6 on the National Institute of Health Stroke Scale (NIHSS), and patient age of at least 18 years.
  • Have no pneumonia according to modified criteria of the U.S. Centers for Disease Control and Prevention (CDC)
  • Consistent with the Constipation of Phlegm-Heat Accumulation type by Traditional Chinese Medicine (TCM) standard
  • Patients or their representatives voluntarily take part in this study and signed the informed consent
Exclusion Criteria
  • Cerebral infarction, transient ischemic attack(TIA)
  • Subarachnoid hemorrhage
  • Proven cerebral embolism caused by tumor, Brain Trauma, cerebral parasitic disease, dysbolismus, fibrillation atrial resulted from rheumatic heart disease, coronary heart disease, and other heart diseases
  • Clinical signs of infection on admission
  • Pregnant or breast-feeding
  • Allergic to rhubarb
  • Preceding or ongoing antibiotic therapy within the last 24 h
  • Participation in another interventional trial
  • Immunosuppressant treatment within the last 30 days
  • Combining severe clinical conditions such as liver, kidney, Hematopoietic System, endocrine system or psychological diseases

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BPlacebo-
Arhubarb-
Primary Outcome Measures
NameTimeMethod
The lung infection rate within 14 days after stroke onset14 days
Secondary Outcome Measures
NameTimeMethod
Global disability on modified Rankin scale at 90 days90 days
NIH stroke scale90 days
Barthel Index90 days
Death rate90 days
Syndrome score by Traditional Chinese Medicine (TCM) standard90 days
Changes in laboratory indexes as safety assessment, including red blood cell(RBC), white blood cell(WBC), platelet(PLT), alanine transaminase (ALT), aspartate transaminase(AST), blood urea nitrogen (BUN), creatinine(Cr) in blood samples; protein,90 days

Trial Locations

Locations (1)

Zhongshan hospital of Fudan University

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath